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Abstract
Atherosclerosis  remains  the  leading  cause  of  death  in  industrialized  societies.  
Apolipoprotein  E  (ApoE)  is  an  attractive  candidate  to  treat  hypercholesterolemia  and 
coronary heart disease, as it is a circulating protein with pleiotropic atheroprotective actions.  
Here,  we  describe  several  "gene  addition"  approaches  and  on-going  developments  to 
achieve  efficient  delivery  and  long-term  expression.    The  use  of  recombinant  viruses  is 
discussed,  including  adeno-associated  viral  vectors  (AAV)  where  technological  advances 
now allow the cross-packaging of different AAV serotypes.  Nonviral delivery systems are 
also  described,  including  plasmids  and  cell-based  therapy.    Finally,  a  radical,  alternative 
technology to gene addition, which has the potential for permanent cure in many genetic 
diseases,  is  reviewed:  "targeted  gene  repair",  which  aims  to  correct  underlying  point 
mutations in-situ.  Synthetic oligonucleotides are designed to bind specifically to defective 
DNA, enabling the cell's own mismatch machinery to recognize and repair the faulty DNA.  
Although  such  gene  editing  technology  has  great  potential  it  remains  inconsistent  and 
difficult to reproduce.
Introduction
Atherosclerosis remains the leading cause of death in industrialized societies.  A significant 
risk factor is raised plasma LDL cholesterol.  This is now effectively treated by statins.  But 
statin  monotherapy  has  limitations,  particularly  if  levels  of  atheroprotective  HDL  are  low.  
Hence, alternative strategies are needed to combat occlusive coronary heart disease (CHD) [1].  
     Somatic  gene  therapy  promises  cure  of  CHD  where  a  gene  is  defective  or  effective 
treatment  where  its  heterologous  overexpression  is  therapeutic.    Circulating  proteins  are 
attractive targets for genetic manipulation.  Here, we focus on apolipoprotein E (ApoE) as a 
candidate to treat hyperlipidaemia and atherosclerosis, describing both gene addition and gene 
editing.  Our commentary is also a paradigm of gene therapy for alternative atheroprotective 
molecules which circulate, including ApoAI-Milano which shows promise in clinical protein 
therapeutics [2].
     ApoE is a polymorphic 34-kDa glycoprotein that mediates hepatic clearance of atherogenic 
remnant lipoproteins.  This action is endorsed by the gross hypercholesterolemia and premature 
atheroma  seen in ApoE-deficient [ApoE(-/-)] mice, or in transgenic mice expressing ApoE 
mutants.    Plasma  ApoE  is  largely  secreted  by  liver  (~90%),  but  other  tissues  including 
macrophages  contribute.    The  rarest  isoform,  ApoE2  differs  from  wild-type  ApoE3  by  an 
Arg158Cys substitution and causes Type III hyperlipidemia [3], while ApoE4 (Cys112Arg) 
produces a dominant hyperlipidemia and is a significant risk factor for CHD as verified by 
meta-analysis [4].
     Importantly,  ApoE  has  multiple  additional  atheroprotective  actions  independent  of 
cholesterol transport [4].  These include antioxidant potential [5], inhibition of vascular smooth 
muscle cell proliferation and migration [6], and our finding that ApoE has anti-platelet and anti-
inflammatory activities by stimulating cellular release of nitric oxide (NO) [7,8].  This suggests 
that ApoE acts locally to restrict atherosclerotic lesion development; indeed, there is compelling 
evidence  that  independently  of  lowering  serum  cholesterol,  ApoE  can  halt  atherosclerosis 
progression and induce lesion regression [9].The Case for ApoE Gene Therapy
Bolus infusion of plasma-purified or recombinant ApoE markedly reduces plasma cholesterol 
levels in rabbits with genetic or diet-induced hypercholesterolaemia, while a longer-term study 
prevents progression of atherosclerosis [10].  Similarly, synthetic peptide mimics of the ApoE 
binding  region  clear  cholesterol-rich  lipoproteins  in  ApoE-deficient  mice  [11].    Studies  in 
transgenic  mice  overexpressing  ApoE  confirm  its  atheroprotective  potential,  protecting  the 
animals  from  diet-induced  or  diabetic  hyperlipidemia  [12,13]  -  though  paradoxically 
supraphysiological  levels  promote  hypertriglyceridemia  [14,15],  albeit  reversible  if  the  C-
terminal domain of ApoE is modified [16].  Finally, macrophage-restricted expression of ApoE 
in transgenic mice [17], or in ApoE(-/-) mice following bone marrow transplantation [18], is 
also able to inhibit atherogenesis. 
     In the 1990s, the majority of preclinical and clinical gene therapy trials used retrovirus-based 
vectors, since their ability to integrate into genomic DNA would ensure long-term expression.  
These included a pilot clinical trial of familial hypercholesterolemia by ex-vivo transduction of 
autologous hepatocytes and subsequent transplantation [19].  However, its invasive, costly and 
time-consuming nature, inherent inefficiency, and safety concerns  transgenes might insert 
into  a  critical  part  of  the  genome,  as  found  during  retroviral  therapy  for  X-linked  severe 
combined immunodeficiency (X-SCID) [20]  have emphasized the need to develop strategies 
for direct in-vivo delivery of therapeutic genes and for long-term expression.
Gene Addition Studies - Adenoviruses (Ad)
The  first  ApoE  gene  transfer  studies  were  reported  10  years  ago  using  recombinant 
adenoviruses (rAd).  They lowered plasma cholesterol in ApoE-deficient mice and after 1-
month aortic atherogenesis had slowed [21].  Adenoviruses are nonenveloped, double-stranded 
DNA.  They exist and propagate only as episomes, but do deliver foreign DNA sequences into 
mammalian liver with an efficiency approaching 100%.  Unfortunately, the therapeutic effect of 
these 1st generation vectors was transient because of cytotoxicity and/or host immunological 
responses against co-expressed viral proteins.  This led to clearance of transduced hepatocytes 
and precluded repeat vector administration.  Nevertheless, the potential to regress advanced 
atherosclerosis was established by cross-breeding ApoE(-/-) and immunodeficient mice and 
then injecting rAd.ApoE3; plaque development was halted and was completely reversed at 6 
months [22].  Recent improvements in rAd constructs, and the introduction of efficient liver-
specific promoters, now offer hope of long-term benefits.  For ApoE expression, these include a 
temperature-sensitive 2nd generation rAd [23], our application of polymerase-deleted vectors 
[24,25], and the development of helper-dependent adenovirus (HD-Ad) [26].  Notwithstanding 
these significant advances, the unexpected and tragic death of a patient undergoing clinical trial 
for a rAd therapeutic [20], has led many groups to critically examine alternative gene transfer 
systems.  
Non-Viral Gene Transfer - Plasmids 
Plasmids have low immunogenicity, can be manufactured in quantity and to high purity, and are 
expressed  episomally,  thereby  making  an  insertional  mutagenesis  highly  unlikely.    Two 
laboratories  have  reported  in-vivo  injection  of  ApoE  plasmids  into  ApoE(-/-)  mice,  both 
choosing  skeletal  muscle  as  the  secretory platform.  Muscle represents an alternative gene 
therapeutic target to liver, being accessible and a stable tissue with little nuclear turnover.  It is 
also highly vascularized and actively secretory and, although it does not normally secrete ApoE, 
nonhepatic, nonmacrophage-derived ApoE is known to be atheroprotective [27].  One group 
reported a sustained lowering of plasma cholesterol [28], despite finding only very low levels of 
secreted ApoE (presumably reflecting the inefficient uptake of plasmids by cells), while our 
own study showed clear inhibition of xanthoma and atherosclerotic plaque formation [29].
Cell Therapy Transplantation of bone marrow from wild-type mice into recipient ApoE(-/-) mice reverses 
their hypercholesterolemia and prevents development of atherosclerosis [18].  Mixing ApoE(-/-) 
bone marrow in increasing amounts with ApoE(+/+) marrow prior to transplanting suggested 
that only 400 ng ApoE/ml was needed to fully normalize plasma cholesterol [30].  This has 
encouraged  cell-based  therapeutic  approaches.    These  include  transducing  ApoE(-/-) 
hematopoietic stem cells (HSCs) ex-vivo with a self-inactivating retroviral vector to express 
high levels of murine ApoE.  Transplantation of these cells reversed both hypercholesterolemia 
and atherosclerosis [31]. 
     A different strategy employs in-vivo ApoE-secreting mini-organs.  One study embedded 
recombinant endothelial cells in Matrigel for intradermal injection into ApoE(-/-) mice; plasma 
cholesterol was halved for over 3 months and atherosclerotic plaque reduced [32].  In another 
investigation, we  encapsulated engineered Chinese hamster ovary (CHO) cells expressing 
human  ApoE3  into  alginate-based  microspheres.    After  confirming  in-vitro  that  ApoE3 
protein was secreted and biologically active, the capsules were implanted into the peritoneum 
of ApoE(-/-) mice.  ApoE was readily detected in plasma and reduced total cholesterol levels, 
whilst increasing atheroprotective HDL [33].  Though we were encouraged by these findings, it 
was clear that the technology must be improved and refined before routine use, particularly for 
long-term treatment to retard or regress atherosclerosis.
AAV - A Safe and Effective Viral Vector? 
Adeno-associated virus (AAV) contains a linear single-stranded DNAgenome and represents a 
family of replication-defective parvoviruses.  They have several advantages for gene transfer: 
they cause no disease in humans and, though wild-type AAV integrates into a 4kb region of 
chromosome 19q using Rep68/78 protein nicking activity [34], provide long-term expression as 
nearly all rAAV persist in target cells as transcriptionally active extrachromosomal (episomal) 
monomeric and multimeric double-stranded forms [35,36].  Indeed, in muscle high and stable 
transgene expression is reported without an immune response.  However, when we injected 
rAAV-ApoE3 into leg muscles of ApoE(-/-) mice, only traces of plasma ApoE were detected 
and the hyperlipidemia was unaffected - though as with plasmid injections, the atherosclerotic 
plaque was significantly reduced [37]. 
     This disappointing outcome can now be explained.  The rAAV-ApoE3 we had employed 
was derived from serotype 2 and, though very effective in-vitro, it is now clear that the different 
serotypes  have  very  variable  transduction  efficiencies  in-vivo.    Thus,  for  muscle-based 
expression  rAAV  serotype-1  produces  100-1000-times  more  secreted  plasma  Factor  IX 
compared to serotype-2 [38].  There have been other important advances in rAAV technology.  
The cloning of additional serotypes has enabled the tropism of rAVV vectors for different target 
tissues to be critically evaluated, while the ability to cross-package rAAV-2 genomes with 
capsid proteins of different serotypes permits considerable experimental flexibility [39].  Of 
note,  is  emerging  evidence  that  AAV2/1,  AAV2/7  and  AAV2/8  are  highly  efficient  at 
transducing  muscle  fibres  of  immunocompetent  mice  compared  to  AAV2/2  [40],  while 
AAV2/8  shows  great  promise  for  gene  transfer  to  liver  [41,42].    Such  improvements  in 
expression are suggested to reflect a much more rapid uncoating of the vector genome [43].
Gene Editing 
A radical, alternative technology to gene transfer, which has the potential for permanent cure 
in many genetic diseases, has been proposed: targeted gene repair.  This elegant strategy 
aims to correct underlying point mutations in-situ and initially used synthetic RNA-DNA 
oligonucleotides, termed RDOs or chimeraplasts.  These were designed to bind specifically 
to defective DNA, enabling the cell's own mismatch machinery to recognize and repair the 
faulty DNA.  Using 68-mer RDOs we have successfully converted the defective ε2 allele 
(C→T) to the fully-functional ε3 allele at a level of ~35% in recombinant CHO cells.  The 
correction was verified by gene sequencing and by isoelectric focusing analysis of secreted 
protein, while prolonged passaging and cloning of cells showed that the corrected allele was 
stably  maintained  [44].    A  preliminary  attempt  to  target  human  APOE2 in  the  liver  of transgenic mice was also promising.   
     However, our attempts to extend the work and correct the dysfunctional human ε4 allele 
in  recombinant  CHO  cells  and  in  EBV-transformed  lymphocytes  from  patients  have 
disappointed.    Conversions  were  noted  by  PCR-RFLP  analysis,  but  were  unstable  and 
corrected clones could not be isolated [45].  Although we ruled out PCR artifacts for the 
initial repair [45], we cannot yet explain our failure though, as noted elsewhere [46], gene 
editing technology remains inconsistent and difficult to reproduce.  Our initial conclusion 
was that manufacturing changes had produced poorer quality reagents [45,47]; in turn, this 
meant we used higher amounts of RDO and delivery vehicle to effect repair, opening the 
possibility of cytotoxic/ apoptotic actions.  An intriguing alternative, or co-possibility, is that 
cells  have  effective  defense  mechanisms  that  counteract  targeted  genome  sequence 
alterations [48].
Concluding Remarks and Future Perspectives
The design of safe and effective gene therapeutic strategies is the goal of many laboratories, 
albeit often a distant one.  In the cardiovascular field its potential clinical significance is 
profound: the prevention and regression of atherosclerotic plaques i.e. reduction in the clinical 
risk of atherosclerosis and treatment of pre-existing disease.  But which vector will emerge to 
clinically deliver ApoE? - a complex question to answer as each has inherent characteristics
which confer both advantages and disadvantages.  
     Of the viral vectors, the new AAV isolates appear promising for safe and efficient gene 
transfer, particularly AAV-2/1 for muscle and AAV-2/8 to transduce liver or muscle [49].  As 
the rate-limiting step in AAV-directed transgene expression is thought to be second-strand 
DNA synthesis, the introduction of self-complementary AAV vectors may further improve 
transduction efficiency [50].  However, one concern prior to widespread clinical trials is 
rAAV  chromosomal  integration.    This  occurs  at  low  frequency  compared  to  episomal 
retention,  but  in  liver  rAAV  preferentially  integrates  into  active  genes  [51]    though 
interestingly rAAV integrants could not be detected following transduction of muscle [52].  
     Despite  the  setback  of  a  fatality,  adenovirus-based  therapies  remain  attractive.    The 
helper-dependent ‘gutless’ rAd vectors have much potential [26], provided current limitations 
of  inefficient  production  and  helper-virus  contamination  can  be  overcome.    Moreover, 
production of effective high-capacity hybrid vectors is underway, coupling the efficient cell-
entry and nuclear targeting properties of Ad to the site-specific integration ability of wild-
type AAV [53].  Lentiviral vectors are also receiving attention for direct in-vivo delivery, as 
unlike other retroviruses, they can transduce a high percentage of nondividing cells, such as 
hepatocytes.  Indeed, recombinant lentiviruses have delivered human ApoE2, E3 & E4 to a 
mouse model of Alzheimer’s disease using direct intracerebral administration [54].
     There  is  renewed  interest  in  non-viral  DNA  (‘naked’  DNA)  delivery,  driven  by 
technological advances, as well as safety considerations.  These include the use of minicircle 
DNA  vectors  devoid  of  bacterial  sequences  [55],  the  design  of  plasmids  which  carry 
scaffold/matrix attached region (S/MAR) for long-term episomal gene expression [56], and 
the use of transposon systems or phage integrase to direct naked DNA integration [57,58].  In 
addition,  there  is  improved  delivery  efficiency,  including  to  liver  by  rapid,  high  volume 
injection (hydrodynamic transfection, by intravenous or regional delivery [59]) or to muscle 
by electric pulsing of injection sites (electroporation) [60].  
     Finally, there is the exciting new technology of gene editing, which unfortunately has 
underperformed  since  the  encouraging  early  reports.    We,  and  others,  now  use  single-
stranded all-DNA oligonucleotides (SSOs), which are end-protected to minimize nuclease 
degradation.  Early data on targeting the APOE4 locus are promising, as conversion of both 
transcribed and non-transcribed strands has been detected.  Whether this can develop into a 
viable  therapeutic  remains  open,  though  this  will  become  clear  once  we  understand  the 
mechanisms by which cells accomplish mismatch repair, an area about which we remain 
largely ignorant.   References
1. Linsel-Nitschke P & Tall AR (2005) HDL as a target in the treatment of atherosclerotic cardiovascular 
disease. Nat. Rev. Drug. Discov 4: 193-205.
2. Nissen  SE,  Tsunoda  T,  Tuzcu  EM  et  al  (2003) Effect  of  recombinant  ApoA-I  Milano  on  coronary 
atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-
300.
3. Mahley  RW,  Huang  Y  &  Rall  SC  Jr  (1999)  Pathogenesis  of  type  III  hyperlipoproteinemia 
(dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-49.
4. Davignon J (2005) Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler. Thromb. Vasc. 
Biol.25: 267-9.
5. Miyata  M  &  Smith  JD  (1996)  Apolipoprotein  E  allele-specific  antioxidant  activity  and  effects  on 
cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14: 55-61.
6. Ishigami  M,  Swertfeger  DK,  Granholm  NA  et  al  (1998)  Apolipoprotein  E  inhibits  platelet-derived 
growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal 
transduction and preventing cell entry to G1 phase. J. Biol. Chem. 273: 20156-61.
7. Riddell DR, Graham A & Owen JS (1997) Apolipoprotein E inhibits platelet aggregation by stimulation of
the L-arginine:nitric oxide pathway.  Implications for vascular disease.  J. Biol. Chem. 272: 89-95.
8. Stannard AK, Riddell DR, Sacre S et al (2001) Cell-derived apolipoprotein E particles inhibit cytokine-
induced vascular cell adhesion molecule-1 expression in endothelial cells. J. Biol. Chem. 276: 46011-
16. 
9. Raffai  RL,  Loeb  SM  &  Weisgraber  KH  (2005)  Apolipoprotein  E  promotes  the  regression  of 
atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler. Thromb.Vasc. Biol.
25: 436-41.
10. Yamada  Y,  Inoue  I,  Kawamura  M  et  al. (1992)  Apolipoprotein  E  prevents  the  progression  of 
atherosclerosis in Watanabe heritable hypercholesterolaemic rabbits. Proc. Natl. Acad. Sci. USA.  86: 
665-669.
11. Nikoulin  IR  &  Curtiss  LK  (1998)  An  apolipoprotein  E  synthetic  peptide  targets  to  lipoproteins  in
plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-
rich lipoproteins in vivo. J. Clin. Invest. 101: 223-34.
12. Shimano H, Yamada Y, Katsuki M et al (1992) Overexpression of apolipoprotein E in transgenic mice: 
marked  reduction  in  plasma  lipoprotein  except  high  density  lipoprotein  and  resistance  against  diet-
induced hypercholesterolemia. Proc. Natl. Acad. Sci. USA 89: 1750-54
13. Yamamoto  K,  Shimano  H,  Shimada  M  et  al  (1995)  Overexpression  of  apolipoprotein  E  prevents 
development of diabetic hyperlipidemia in transgenic mice. Diabetes 44: 580-5
14. Huang Y, Liu XQ, Rall SC et al. (1998) Overexpression and accumulation of apolipoprotein E as a 
cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-93
15. Huang Y, Ji ZS, Brecht WJ et al. (1999) Overexpression of apolipoprotein E3 in transgenic rabbits 
causes  combined  hyperlipidemia  by  stimulating  hepatic  VLDL  production  and  impairing  VLDL 
lipolysis. Arterioscler Thromb. Vasc. Biol. 19: 2952-9.
16. Kypreos KE, van Dijk KW, Havekes LM et al (2005) Generation of a Recombinant Apolipoprotein E 
Variant with Improved Biological Functions: HYDROPHOBIC RESIDUES (LEU-261, TRP-264, PHE-265, 
LEU-268, VAL-269) OF apoE CAN ACCOUNT FOR THE apoE-INDUCED HYPERTRIGLYCERIDEMIA. J. 
Biol. Chem. 280: 6276-84.
17. Bellosta  S,  Mahley  RW,  Sanan  DA  et  al  (1995)  Macrophage-specific  expression  of  human 
apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. 
Invest. 96: 2170-9. 
18. Linton MF, Atkinson JB & Fazio S (1995) Prevention of atherosclerosis in apolipoprotein E-deficient 
mice by bone marrow transplantation.  Science 267: 1034-7.
19. Grossman M, Rader DJ, Muller DW et al (1995) A pilot study of ex vivo gene therapy for homozygous 
familial hypercholesterolaemia. Nat Med. 1: 1148-54. 
20. Roberts JP (2004) Gene therapy’s fall and rise (again) The Scientist 18: 22-24.
21. Kashyap VS, Santamarina-Fojo S, Brown DR et al (1995) Apolipoprotein E deficiency in mice: gene 
replacement and prevention of atherosclerosis using adenovirus vectors. J. Clin. Invest. 96: 1612-20.
22. Desurmont C, Caillaud JM, Emmanuel F et al (2000) Complete atherosclerosis regression after human 
ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler. Thromb. Vasc. Biol. 20: 435-42.
23. Tsukamoto K, Tangirala R, Chun SH et al (1999) Rapid regression of atherosclerosis induced by liver-
directed gene transfer of apoE in apoE-deficient mice. Arterioscler.Thromb.Vasc.Biol. 19: 2162-70.
24. Harris JD, Graham IR, Schepelmann S et al (2002) Acute regression of advanced and retardation of early aortic  atheroma  in  immunocompetent  apolipoprotein  (apo)  E-deficient  mice  by  injection  of  a 
recombinant adenovirus [E2-, E3-, polymerase-deleted] vector expressing  human apoE.  Hum. Mol. 
Gen. 11: 43-58.
25. Harris JD, Graham IR, Schepelmann S et al (2005) Retardation of atherosclerosis in immunocompetent 
apolipoprotein  (apo)  E-deficient  mice  following  liver-directed  administration  of  a  [E1−,  E3−, 
polymerase−]  adenovirus  vector  containing  the  elongation  factor-1α  promoter  driving  expression  of 
human apoE cDNA. Gene Ther Mol Biol 9: 23-32.
26. Kim IH, Jozkowicz A, Piedra PA et al (2001) Lifetime correction of genetic deficiency in mice with a 
single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA. 98: 13282-7.
27. Wientgen H, Thorngate FE, Omerhodzic S et al (2004) Subphysiologic apolipoprotein E (ApoE) plasma 
levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler. Thromb. 
Vasc. Biol. 24: 1460-5.
28. Rinaldi  M,  Catapano  AL,  Parrella  P  et  al  (2000)  Treatment  of  severe  hypercholesterolemia  in 
apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Ther. 7: 1795-801.
29. Athanasopoulos T, Dunckley MG, Drew J et al (2000) Reduction of xanthoma and aortic atheroma in apoE-
/- mice following intramuscular injection of a plasmid vector expressing human apoE. Hum. Molec. Gen. 9:
2545-51.
30. Hasty AH, Linton JF, Swift LL et al (1999) Determination of the lower threshold of apolipoprotein E 
resulting in remnant lipoprotein clearance. J. Lipid Res. 40: 1529-38.
31. Gough  PJ  &  Raines  EW  (2003)  Gene  therapy  of  apolipoprotein  E-deficient  mice  using  a  novel 
macrophage-specific retroviral vector. Blood. 101: 485-91.
32. Cioffi L, Sturtz FG, Wittmer S et al (1999) A novel endothelial cell-based gene therapy platform for the 
in vivo delivery of apolipoprotein E. Gene Ther. 6: 1153-9.
33. Tagalakis  AD,  Diakonov  IA,  Graham  IR  et  al  (2005)  Apolipoprotein  E  delivery  by  peritoneal 
implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient 
mice. Biochim. Biophys. Acta. 1686: 190-9. 
34. Jang MY, Yarborough OH 3rd, Conyers GB et al (2005) Stable secondary structure near the nicking site for 
adeno-associated virus type 2 Rep proteins on human chromosome 19.  J. Virol. 79: 3544-56.
35. Nakai H, Yant SR, Storm TA et al (2001) Extrachromosomal recombinant adeno-associated virus vector 
genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75: 6969-76.
36. Duan D, Sharma P, Yang J et al (1998) Circular intermediates of recombinant adeno-associated virus have 
defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol.
72: 8568-77. 
37. Harris JD,  Schepelmann    S,    Athanasopoulos T  et  al  (2002)  Inhibition  of  atherosclerosis  in 
apolipoprotein-E-deficient  mice  following  muscle  transduction  with  adeno-associated  virus  vectors 
encoding human apolipoprotein-E. Gene Ther. 9: 21-29.
38. Chao H, Liu Y, Rabinowitz J et al. (2000) Several log increase in therapeutic transgene delivery by 
distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-23.
39. Rabinowitz JE, Rolling F, Li C et al (2002) Cross-packaging of a single adeno-associated virus (AAV) 
type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol.
76: 791-801.
40. Louboutin  J-P,  Wang  L & Wilson JM (2005) Gene transfer into skeletal muscle using novel AAV 
serotypes. J. Gen Med., in press.
41. Lebherz C, Gao G, Louboutin JP et al (2004) Gene therapy with novel adeno-associated virus vectors 
substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene 
Med. 6: 663-72.
42. Davidoff AM, Gray JT, Ng CYC et al (2005) Comparison of the ability of adeno-associated viral vectors 
pseudotyped with serotype 2, 5 and 8 capsid proteins to mediate efficient transduction of the liver in 
murine and nonhuman primate models. Mol. Therap, in press.
43. Thomas CE, Storm TA, Huang Z et al (2004) Rapid uncoating of vector genomes is the key to efficient liver 
transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78: 3110-22.
44. Tagalakis  AD,  Graham  I,  Riddell  DR,  Dickson  JG  &  Owen  JS  (2001)  Gene  correction  of  the 
apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. J. Biol. Chem. 276:
13226-13230.
45. Tagalakis AD, DicksonG, Owen JS & Simons JP (2005) Gene correction of human apolipoprotein (apo) 
E4 to apoE3 in vitro using synthetic RNA/DNA oligonucleotides (chimeraplasts). J. Mol. Neurosci., in 
press.
46. Taubes  G  (2002)  Gene  therapy.  The  strange  case  of  chimeraplasty.  Science.  2002  Dec  13;298
(5601):2116-20.
47. Manzano A, Mohri Z, Sperber G, Ogris M, GrahamI, Dickson G & Owen JS (2003) Failure to generate 
atheroprotective  apolipoprotein  AI  phenotypes  using  synthetic  RNA/DNA  oligonucleotides (chimeraplasts). J. Gene Med. 5: 795-802.  
48. Olsen PA, Randol M & Krauss S (2005) Implications of cell cycle progression on functional sequence 
correction by short single-stranded DNA oligonucleotides. Gene Ther., in press.
49. Wang Z, Zhu T, Qiao C et al (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle 
and heart.  Nat. Biotechnol. 23: 321- 28. 
50. McCarty DM, Monahan  PE & Samulski RJ (2001) Self-complementary recombinant adeno-associated 
virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8: 1248-
54.
51. Nakai H, Wu X, Fuess S et al (2005) Large-scale molecular characterization of adeno-associated virus 
vector integration in mouse liver. J. Virol. 79: 3606-14.
52. Schnepp BC, Clark KR, Klemanski DL et al (2003) Genetic fate of recombinant adeno-associated virus 
vector genomes in muscle. J. Virol. 77: 3495-504. 
53. Goncalves MA, van der Velde I, Knaan-Shanzer S et al (2004) Stable transduction of large DNA by high-
capacity adeno-associated virus/adenovirus hybrid vectors. Virology 321: 287-96.
54. Dodart JC, Marr RA, Koistinaho M et al (2005) Gene delivery of human apolipoprotein E alters brain 
Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA.  102: 1211-6.
55. Chen ZY, He CY & Kay MA (2005) Improved production and purification of minicircle DNA vector free 
of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum. Gene Ther. 16: 
126-31.
56. Jenke AC, Stehle IM, Herrmann F et al (2004) Nuclear scaffold/matrix attached region modules linked to 
a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl. 
Acad. Sci. USA. 101: 11322-7.
57. Thomas CE, Erhardt A & Kay MA (2003) Progress and problems with the use of viral vectors for gene 
therapy. Nat. Rev. Genet. 4: 346-58.
58. Ehrhardt A, Xu H, Huang Z et al (2005) A direct comparison of two nonviral gene therapy vectors for 
somatic  integration:  in  vivo  evaluation  of  the  bacteriophage  integrase  φc31and  the  Sleeping  Beauty
transposase. Mol. Ther, in press. 
59. Zhang X, Dong X, Sawyer GJ et al (2004) Regional hydrodynamic gene delivery to the rat liver with 
physiological volumes of DNA solution.  J. Gene Med. 6: 693-703.
60. Aihara H & Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:
867-70.
.
.   